Skip to main content

Advertisement

Table 2 Summary of adverse events (no. (%)) in patients with osteoarthritis who received risedronate or placebo

From: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

  Placebo Risedronate
  (n = 98) 5 mg/day (n = 96) 15 mg/day (n = 90)
Patients with AEs 94 (96%) 95 (99%) 84 (93%)
Dropouts due to AEs 12 (12%) 7 (7%) 10 (11%)
Overall GI AEs 15 (15%) 16 (17%) 7 (8%)
   Abdominal pain 6 (6%) 7 (7%) 3 (3%)
   Dyspepsia 7 (7%) 7 (7%) 3 (3%)
   Gl disorder 3 (3%) 1 (1%) 1 (1%)
  1. AE, adverse event; GI, gastrointestinal.